Biosimilar Inspection Modernization Act of 2025
Sponsored By: Senator Sen. Budd, Ted [R-NC]
Introduced
Summary
Modernize FDA inspections for biosimilar manufacturers. This bill would push Health and Human Services to expand use of international agreements and remote assessments, update inspection tools for risk-based reviews, and publish a plan to strengthen domestic inspections.
Show full summary
- Foreign and international manufacturers: Requires a public meeting within 180 days and a report within 180 days after that meeting on using mutual recognition agreements to inspect biosimilar product establishments and on expanding MRAs to include remote assessments and trusted foreign partners.
- FDA inspectors and inspection process: Directs updates to inspection processes and tools so the agency can perform more risk-based reviews, increase use of remote regulatory assessments under FDA guidance, and maximize alternative tools to boost efficiency.
- Sponsors of 351(k) applications and domestic facilities: Requires a strategic plan within 1 year to address recruiting and retaining inspection staff, challenges specific to domestic biosimilar facilities, improve internal FDA communication, and expand outreach to applicants about inspection needs and earlier resolution of inspection questions.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
Modernize biosimilar facility inspections
This bill would require the HHS Secretary (through the FDA) to modernize inspections of facilities that make biosimilar drugs. Within 1 year, the Secretary would publish a strategic plan on hiring and keeping inspection staff, inspection challenges for biosimilar facilities, better internal FDA coordination, and more communication with sponsors of 351(k) applications. The Secretary would update inspection tools to use a risk-based approach and increase remote regulatory assessments consistent with FDA guidance dated June 24, 2025. The Secretary would hold a public meeting on mutual recognition agreements within 180 days and deliver a recommendations report to congressional health committees within 180 days after that meeting. This mainly affects biosimilar drug makers and FDA inspection staff.
Free Policy Watch
You just read the policy. Now see what it costs you.
Pick a topic. PRIA runs your household against live legislation and sends you a free personalized readout.
Pick a topic to get started
Sponsors & CoSponsors
Sponsor
Sen. Budd, Ted [R-NC]
NC • R
Cosponsors
Sen. Hassan, Margaret Wood [D-NH]
NH • D
Sponsored 12/16/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Take the PRIA Score to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in